Dasatinib combined with weekly administration of vincristine as effective therapy in sudden or resistant Ph+ lymphoid blast crisis of chronic myeloid leukaemia

British Journal of Haematology

Volumn 159, Issue 5, 2012, Pages 0-

  Breccia, Massimo ^a   Serrao, Alessandra ^a   Salaroli, Adriano ^a   Loglisci, Giuseppina ^a   Zacheo, Irene ^a   Alimena, Giuliana ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Chronic myeloid leukaemia; Dasatinib; Lymphoid blast crisis

Indexed keywords

DASATINIB; IMATINIB; VINCRISTINE;

ADULT; BLAST CELL CRISIS; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; DRUG MEGADOSE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOPHENOTYPING; LETTER; LEUKEMIA REMISSION; PERIPHERAL NEUROPATHY; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; TREATMENT RESPONSE;

EID: 84869096420     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12079     Document Type: Letter

References (8)

1. Alimena, G., Breccia, M., Latagliata, R., Carmosino, I., Russo, E., Biondo, F., Diverio, D., Mancini, M., Nanni, M. & Mandelli, F. (2006) Sudden blast crisis in patients with Philadelphia chromosome-positive chronic myeloid leukemia who achieved complete cytogenetic remission after imatinib therapy. Cancer, 107, 1008-1013.
2. Cortes, J., Kim, D.W., Raffoux, E., Martinelli, G., Ritchie, E., Roy, L., Coutre, S., Corm, S., Hamerschlak, N., Tang, J.L., Hochhaus, A., Khoury, H.J., Brümmendorf, T.H., Michallet, M., Rege-Cambrin, G., Gambacorti-Passerini, C., Radich, J.P., Ernst, T., Zhu, C., Van Tornout, J.M. & Talpaz, M. (2008) Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia, 22, 2176-2183.
3. Druker, B.J., Sawyers, C.L., Kantarjian, H., Resta, D.J., Reese, S.F., Ford, J.M., Capdeville, R. & Talpaz, M. (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. New England Journal of Medicine, 344, 1038-1042.
4. Jabbour, E., Kantarjian, H., O'Brien, S., Rios, M.B., Abruzzo, L., Verstovsek, S., Garcia-Manero, G. & Cortes, J. (2006) Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate. Blood, 107, 480-482.
5. Milojkovic, D., Ibrahim, A., Reid, A., Foroni, L., Apperley, J. & Marin, D. (2012) Efficacy of combining dasatinib and FLAG-IDA for patients with chronic myeloid leukemia in blastic transformation. Haematologica, 97, 473-474.
6. Rea, D., Legros, L., Raffoux, E., Raffoux, E., Thomas, X., Turlure, P., Maury, S., Dupriez, B., Pigneux, A., Choufi, B., Reman, O., Stéphane, D., Royer, B., Vigier, M., Ojeda-Uribe, M., Recher, C., Dombret, H., Huguet, F., Rousselot, P., Intergroupe Français des Leucémies Myéloïdes Chronique & Group for Research in Adult Acute Lymphoblastic Leukemia. (2006) High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia. Leukemia, 20, 400-403.
7. Saglio, G., Hochhaus, A., Goh, Y.T., Masszi, T., Pasquini, R., Maloisel, F., Erben, P., Cortes, J., Paquette, R., Bradley-Garelik, M.B., Zhu, C. & Dombret, H. (2010) Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. Cancer, 116, 3852-3861.
8. Shah, N.P. (2008) Advanced CML: therapeutic options for patients in accelerated and blast phases. Journal of the National Comprehensive Cancer Network, 6, Suppl 2, S31-S36.